Neuburgh Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Neuburgh Advisers’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$274K	Hold	4,408	–	–	0.01%	609
2019 Q2	$314K	Buy	4,408 +423	+11%	+$31.2K	0.01%	579
2019 Q1	$313K	Hold	3,985	–	–	0.01%	569
2018 Q4	$337K	Hold	3,985	–	–	0.01%	500
2018 Q3	$682K	Buy	3,985 +106	+3%	+$16K	0.02%	381
2018 Q2	$501K	Hold	3,879	–	–	0.02%	426
2018 Q1	$400K	Hold	3,879	–	–	0.01%	468
2017 Q4	$331K	Buy	3,879 +846	+28%	+$73.3K	0.01%	526
2017 Q3	$258K	Buy	3,033 +600	+25%	+$47.5K	0.01%	540
2017 Q2	$184K	Buy	2,433 +1,128	+86%	+$78.9K	0.01%	594
2017 Q1	$86K	Buy	1,305 +247	+23%	+$16.2K	﹤0.01%	653
2016 Q4	$67K	Buy	+1,058	New	+$66.8K	﹤0.01%	680

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Neuburgh Advisers's LGND Position: Q3 2019 in Review

Neuburgh Advisers held its Ligand Pharmaceuticals (LGND) position steady in Q3 2019 at 4,408 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #609.

Neuburgh Advisers first reported a position in LGND in Q4 2016 and has held it in 12 quarters since. The position peaked at $682K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Neuburgh Advisers held 4,408 shares of Ligand Pharmaceuticals worth $274K as of Q3 2019.
Neuburgh Advisers left its Ligand Pharmaceuticals share count unchanged in Q3 2019.
Ligand Pharmaceuticals made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #609 holding.
Neuburgh Advisers first reported a position in Ligand Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Neuburgh Advisers's Ligand Pharmaceuticals position peaked at $682K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.